This animation provides discusses heart failure symptoms and treatment options. CCM therapy is introduced including the indications for use, recommendations for patient selection, and a brief description of how cardiac contractility works in the heart. The procedure is reviewed as well as clinical trial results.
- October 26, 2021 - U.S. Food and Drug Administration approved a modification of labeling for the Optimizer® Smart medical device, allowing the removal of “normal sinus rhythm” (NSR) from the indications for use statement as of 10/26/2021. Please note that this presentation was done prior to this FDA update.
Comments 0
Login to view comments.
Click here to Login
